Federal regulators have cleared the first medicine ever approved specifically to treat Alexander disease, a rare and often fatal brain disorder that until now had no treatment beyond managing its symptoms. The drug arrives with a list price that ranks among the highest of any medicine on the market, a figure that reflects both how rare the condition is and how narrow the patient population will remain.
A first approval for a disease with no prior treatment
The Food and Drug Administration approved ZANVASTRO, known chemically as zilganersen, for use in both pediatric and adult patients with Alexander disease. Developed by Ionis Pharmaceuticals, it is described by the company as the first and only disease-modifying treatment for the condition, meaning it is designed to slow the underlying biological process driving the disease rather than simply treating its symptoms as they appear.
Alexander disease is an ultra-rare, progressive neurological disorder that can affect motor function, cognition, and both autonomic and gastrointestinal systems depending on when it appears and how it progresses. Cases that begin in infancy tend to be the most severe, often proving fatal within the first years of life, while forms that appear later in childhood or adulthood can progress more slowly but still cause significant and worsening disability over time.
How zilganersen targets the disease at its source
Zilganersen is an RNA-targeted medicine built on Ionis’s antisense technology, a drug class designed to interrupt disease-causing proteins before the body produces them. In Alexander disease, mutations drive overproduction of a protein called glial fibrillary acidic protein, or GFAP, inside star-shaped brain cells known as astrocytes. That buildup is thought to underlie much of the damage seen in the disease, and zilganersen works by reducing how much GFAP the body makes in the first place, rather than by addressing the mutation itself.
The drug is delivered as an intrathecal injection, meaning it is administered directly into the fluid surrounding the spinal cord rather than through a pill or a standard intravenous line, a delivery method commonly used for antisense drugs intended to act on the brain and spinal cord. Antisense technology works by binding to a strand of messenger RNA before it can be translated into protein, effectively silencing part of the instructions the mutated gene is sending, a mechanism Ionis has used in several other approved medicines for rare neurological and neuromuscular conditions.
A disease caused by a single mutated gene
Alexander disease is caused by mutations in the GFAP gene itself, most of which arise spontaneously rather than being inherited from a parent. Because the mutation directly affects how astrocytes function, and astrocytes play a central role in supporting and regulating other brain cells, the downstream effects can touch movement, feeding, breathing, and cognitive development depending on which regions of the brain and spinal cord are most affected. Diagnosis typically follows genetic testing after imaging or clinical symptoms raise suspicion of the disease, since the condition is rare enough that many physicians will encounter only a handful of cases, or none at all, over an entire career.
A quarterly dose delivered by spinal injection
Patients receive a 50 milligram dose of ZANVASTRO once every three months, according to Ionis. That interval sets it apart from many chronic neurological treatments that require monthly or more frequent dosing, though it still means patients face repeated intrathecal procedures indefinitely as part of ongoing care.
A price tag above a million dollars a year
ZANVASTRO carries a list price of $285,000 per dose, according to reporting from MedCity News. Dosed quarterly, that works out to roughly $1.14 million a year before any rebates, discounts, or insurance negotiations are factored in, placing it among the most expensive medicines available in the United States.
List prices in that range are common for ultra-rare disease drugs, where a manufacturer has to recover development costs across a patient population that may number only in the hundreds worldwide. Alexander disease is exactly that kind of condition: rare enough that large randomized trials of the kind used for more common illnesses were not feasible, and the price reflects a small, specialized market rather than mass demand.
A voucher and a licensing deal beyond the approval itself
The approval came with a Priority Review Voucher awarded alongside it, according to Ionis, a regulatory incentive that can be used to speed FDA review of a future drug or sold to another company, since such vouchers have historically traded for tens of millions of dollars on their own. Separately, Ionis has already lined up commercial partners for markets outside the country: in June, Recordati licensed rights to sell the drug outside the United States for $30 million upfront plus royalties tied to future sales, a deal that positions the treatment to reach patients well beyond the American market once local regulatory approvals follow.
For families affected by Alexander disease, the approval marks a shift from a diagnosis that came with essentially no targeted treatment options to one with an approved therapy, even as the cost of that therapy raises separate questions about insurance coverage and access that will likely play out over the months following the drug’s launch.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
